Literature DB >> 25536179

Calcium signaling regulates ventricular hypertrophy during development independent of contraction or blood flow.

Nicholas D Andersen1, Kapil V Ramachandran2, Michelle M Bao3, Margaret L Kirby4, Geoffrey S Pitt5, Mary R Hutson3.   

Abstract

In utero interventions aimed at restoring left ventricular hemodynamic forces in fetuses with prenatally diagnosed hypoplastic left heart syndrome failed to stimulate ventricular myocardial growth during gestation, suggesting chamber growth during development may not rely upon fluid forces. We therefore hypothesized that ventricular hypertrophy during development may depend upon fundamental Ca(2+)-dependent growth pathways that function independent of hemodynamic forces. To test this hypothesis, zebrafish embryos were treated with inhibitors or activators of Ca(2+) signaling in the presence or absence of contraction during the period of chamber development. Abolishment of contractile function alone in the setting of preserved Ca(2+) signaling did not impair ventricular hypertrophy. In contrast, inhibition of L-type voltage-gated Ca(2+) influx abolished contraction and led to reduced ventricular hypertrophy, whereas increasing L-type voltage-gated Ca(2+) influx led to enhanced ventricular hypertrophy in either the presence or absence of contraction. Similarly, inhibition of the downstream Ca(2+)-sensitive phosphatase calcineurin, a known regulator of adult cardiac hypertrophy, led to reduced ventricular hypertrophy in the presence or absence of contraction, whereas hypertrophy was rescued in the absence of L-type voltage-gated Ca(2+) influx and contraction by expression of a constitutively active calcineurin. These data suggest that ventricular cardiomyocyte hypertrophy during chamber formation is dependent upon Ca(2+) signaling pathways that are unaffected by heart function or hemodynamic forces. Disruption of Ca(2+)-dependent hypertrophy during heart development may therefore represent one mechanism for impaired chamber formation that is not related to impaired blood flow.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Calcium; Congenital heart defects; Development; Hypertrophy; Hypoplastic left heart syndrome

Mesh:

Substances:

Year:  2014        PMID: 25536179      PMCID: PMC4346462          DOI: 10.1016/j.yjmcc.2014.12.016

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  41 in total

1.  A cluster of hypoplastic left heart malformation in Baltimore, Maryland.

Authors:  K S Kuehl; C A Loffredo
Journal:  Pediatr Cardiol       Date:  2006 Jan-Feb       Impact factor: 1.655

2.  Cellular and molecular analyses of vascular tube and lumen formation in zebrafish.

Authors:  Suk-Won Jin; Dimitris Beis; Tracy Mitchell; Jau-Nian Chen; Didier Y R Stainier
Journal:  Development       Date:  2005-10-26       Impact factor: 6.868

3.  Regionalized sequence of myocardial cell growth and proliferation characterizes early chamber formation.

Authors:  Alexandre T Soufan; Gert van den Berg; Jan M Ruijter; Piet A J de Boer; Maurice J B van den Hoff; Antoon F M Moorman
Journal:  Circ Res       Date:  2006-08-03       Impact factor: 17.367

4.  Revisiting animal models of aortic stenosis in the early gestation fetus.

Authors:  Pirooz Eghtesady; Erik Michelfelder; Mekibib Altaye; Edgar Ballard; Russel Hirsh; Robert H Beekman
Journal:  Ann Thorac Surg       Date:  2007-02       Impact factor: 4.330

5.  Hypoplastic left heart syndrome: can we change the rules of the game?

Authors:  Jack Rychik
Journal:  Circulation       Date:  2014-07-22       Impact factor: 29.690

6.  Remodeling of chick embryonic ventricular myoarchitecture under experimentally changed loading conditions.

Authors:  D Sedmera; T Pexieder; V Rychterova; N Hu; E B Clark
Journal:  Anat Rec       Date:  1999-02-01

7.  Fetal aortic valve stenosis and the evolution of hypoplastic left heart syndrome: patient selection for fetal intervention.

Authors:  Kaarin Mäkikallio; Doff B McElhinney; Jami C Levine; Gerald R Marx; Steven D Colan; Audrey C Marshall; James E Lock; Edward N Marcus; Wayne Tworetzky
Journal:  Circulation       Date:  2006-03-13       Impact factor: 29.690

8.  Management of 239 patients with hypoplastic left heart syndrome and related malformations from 1993 to 2007.

Authors:  Jeffrey P Jacobs; Sean M O'Brien; Paul J Chai; Victor O Morell; Harald L Lindberg; James A Quintessenza
Journal:  Ann Thorac Surg       Date:  2008-05       Impact factor: 4.330

9.  Establishment of cardiac cytoarchitecture in the developing mouse heart.

Authors:  Alain Hirschy; Franziska Schatzmann; Elisabeth Ehler; Jean-Claude Perriard
Journal:  Dev Biol       Date:  2005-12-09       Impact factor: 3.582

10.  Functional modulation of cardiac form through regionally confined cell shape changes.

Authors:  Heidi J Auman; Hope Coleman; Heather E Riley; Felix Olale; Huai-Jen Tsai; Deborah Yelon
Journal:  PLoS Biol       Date:  2007-03       Impact factor: 8.029

View more
  4 in total

1.  Calcium handling precedes cardiac differentiation to initiate the first heartbeat.

Authors:  Richard Cv Tyser; Antonio Ma Miranda; Chiann-Mun Chen; Sean M Davidson; Shankar Srinivas; Paul R Riley
Journal:  Elife       Date:  2016-10-11       Impact factor: 8.140

2.  A Meta-Analysis of Bioelectric Data in Cancer, Embryogenesis, and Regeneration.

Authors:  Pranjal Srivastava; Anna Kane; Christina Harrison; Michael Levin
Journal:  Bioelectricity       Date:  2021-03-16

3.  Investigation of human iPSC-derived cardiac myocyte functional maturation by single cell traction force microscopy.

Authors:  Matthew Wheelwright; Zaw Win; Jennifer L Mikkila; Kamilah Y Amen; Patrick W Alford; Joseph M Metzger
Journal:  PLoS One       Date:  2018-04-04       Impact factor: 3.240

4.  The CaMKII phosphorylation site Thr1604 in the CaV1.2 channel is involved in pathological myocardial hypertrophy in rats.

Authors:  Jingyuan Li; Siqi Wang; Jie Zhang; Yan Liu; Xi Zheng; Fan Ding; Xuefei Sun; Meimi Zhao; Liying Hao
Journal:  Channels (Austin)       Date:  2020-12       Impact factor: 2.581

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.